Marko Jukič
University of Ljubljana
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marko Jukič.
Current Medicinal Chemistry | 2013
Marko Jukič; Danijel Kikelj; Marko Anderluh
Voltage-gated sodium channels are large transmembrane protein complexes responsible for the propagation and transmission of electrical impulses through nerve, muscle and endocrine cells and cell systems. Dysregulated expression and/or functional changes of ion channel isoforms are found in many associated pathological conditions. In such cases, modulation of voltage gated sodium channels (Na(V) channels) is a recognised approach in medicinal chemistry. Multiple small-molecule active compounds are used for a plethora of Na(V) channel-linked indications, for example epilepsy and CNS disorders, arrhythmia, stroke and pain states such as congenital analgesia/hyperalgesia and neuropathic pain. As existent Na(V) channel modulators suffer mainly from selectivity issues and thus exert significant side effects, novel and selective Na(V) channel modulators would be beneficial. Consequently, the increased research on voltage-gated sodium channels has led to a large number of novel compounds that exploit classic binding site selectivity with state-dependence or functional selectivity. Such compounds offer selective targeting and new possibilities for studying the physiology of Na(V) channels and pathophysiology of the associated ailment conditions. This review consolidates the recent literature on Na(V) 1.3, 1.7 and 1.8 channel isoform selective and/or state-dependent modulators. In particular, their structure-activity relationship is illustrated, especially in the context of selectivity on a particular isoform, and their applicability in the therapy of neuropathic pain is described.
Bioorganic & Medicinal Chemistry Letters | 2017
Martina Hrast; Kaja Rožman; Marko Jukič; Delphine Patin; Stanislav Gobec; Matej Sova
MurA is an intracellular bacterial enzyme that is essential for peptidoglycan biosynthesis, and is therefore an important target for antibacterial drug discovery. We report the synthesis, in silico studies and extensive structure-activity relationships of a series of quinazolinone-based inhibitors of MurA from Escherichia coli. 3-Benzyloxyphenylquinazolinones showed promising inhibitory potencies against MurA, in the low micromolar range, with an IC50 of 8µM for the most potent derivative (58). Furthermore, furan-substituted quinazolinones (38, 46) showed promising antibacterial activities, with MICs from 1µg/mL to 8µg/mL, concomitant with their MurA inhibitory potencies. These data represent an important step towards the development of novel antimicrobial agents to combat increasing bacterial resistance.
MedChemComm | 2015
Tihomir Tomašič; Dominik Nabergoj; Sanja Vrbek; Nace Zidar; Žiga Jakopin; Aleš Žula; Žiga Hodnik; Marko Jukič; Marko Anderluh; Janez Ilaš; Marija Sollner Dolenc; Jean Peluso; Geneviève Ubeaud-Séquier; Christian D. Muller; Lucija Peterlin Mašič; Danijel Kikelj
The marine alkaloids clathrodin, oroidin, and hymenidin, which were isolated from Agelas sponges, possess diverse biological activities. Herein, we describe the design of a library of their analogues and the evaluation of their apoptosis-inducing activities against the human hepatocellular carcinoma HepG2 and acute monocytic leukaemia THP-1 cell lines. The screening of the complete library of 96 compounds using the HepG2 cell line allowed us to determine key structural elements and physicochemical properties that are responsible for the apoptosis-inducing activity. The indole-based compounds 24c, 28c, 29c, and 34c were found to be the most potent inducers of apoptosis in HepG2 and THP-1 cell lines with EC50 values in the low micromolar range. Cell cycle analysis assays confirmed that compounds 24c, 28c, 29c, and 34c induce the apoptosis of THP-1 cells at 25 μM, which highlights these oroidin analogues as interesting candidates for further evaluation of their anticancer activity.
Molecular Diversity | 2013
Marko Jukič; Aleksandra Ɖorđević; Jelena Lazarević; Martina Gobec; Andrija Smelcerovic; Marko Anderluh
We report a small, focused library of 30 diverse 2-amino-5-alkylidene-thiazol-4-ones that was assayed in a whole-cell antibacterial screen against a panel of several bacterial strains and a yeast. Most of the compounds exhibited modest to significant antibacterial activity against Pseudomonas aeruginosa, Bacillus subtilis and Staphylococcus aureus, and no activity against Salmonella typhimurium and Escherichia coli. The antibacterial activity depends markedly upon substituents on the thiazol-4-one core, and the most potent compound assayed (
Medicinal Research Reviews | 2018
Lena Decuyper; Marko Jukič; Izidor Sosič; Aleš Žula; Matthias D'hooghe; Stanislav Gobec
Chemical Biology & Drug Design | 2018
Martina Hrast; Marko Jukič; Delphine Patin; Julie Tod; Christopher G. Dowson; David I. Roper; Hélène Barreteau; Stanislav Gobec
(Z)
Journal of Chemical Information and Modeling | 2017
Marko Jukič; Janez Konc; Stanislav Gobec; Dušanka Janežič
Biochimica et Biophysica Acta | 2019
Dunja Urbančič; Anita Kotar; Alenka Šmid; Marko Jukič; Stanislav Gobec; Lars-Göran Mårtensson; Janez Plavec; Irena Mlinarič-Raščan
(Z)-4-((2-(4-methylpiperidin-1-yl)-4-oxothiazol-5(4H)-ylidene)methyl)benzonitrile) reached a minimal inhibitory concentration (MIC) value of
Drug Development Research | 2018
Marko Jukič; Stanislav Gobec; Matej Sova
Chemistry: A European Journal | 2018
Lena Decuyper; Sari Deketelaere; Lore Vanparys; Marko Jukič; Izidor Sosič; Eric Sauvage; Ana Maria Amoroso; Olivier Verlaine; Bernard Joris; Stanislav Gobec; Matthias D'hooghe
10\,\upmu \hbox {g/mL}